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Abstract The goal of targeted cancer therapies is to
specifically block oncogenic signalling, thus maximising
efficacy, while reducing side-effects to patients. The
gamma-secretase (GS) complex is an attractive therapeutic
target in haematological malignancies and solid tumours
with major pharmaceutical activity to identify optimal
inhibitors. Within GS, nicastrin (NCSTN) offers an
opportunity for therapeutic intervention using blocking
monoclonal antibodies (mAbs). Here we explore the role of
anti-nicastrin monoclonal antibodies, which we have
developed as specific, multi-faceted inhibitors of prolifer-
ation and invasive traits of triple-negative breast cancer
cells. We use 3D in vitro proliferation and invasion assays
as well as an orthotopic and tail vail injection triple-neg-
ative breast cancer in vivo xenograft model systems.
RNAScope assessed nicastrin in patient samples. Anti-
NCSTN mAb clone-2H6 demonstrated a superior anti-
tumour efficacy than clone-10C11 and the RO4929097
small molecule GS inhibitor, acting by inhibiting GS
enzymatic activity and Notch signalling in vitro and
in vivo. Confirming clinical relevance of nicastrin as a
target, we report evidence of increased NCSTN mRNA
levels by RNA in situ hybridization (RNAScope) in a large
cohort of oestrogen receptor negative breast cancers, con-
ferring independent prognostic significance for disease-free
survival, in multivariate analysis. We demonstrate here that
targeting NCSTN using specific mAbs may represent a
novel mode of treatment for invasive triple-negative breast
cancer, for which there are few targeted therapeutic
options. Furthermore, we propose that measuring NCSTN
in patient samples using RNAScope technology may serve
as companion diagnostic for anti-NCSTN therapy in the
clinic.
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Introduction
The vision of selective targeting was introduced a century
ago by Paul Ehrlich who hypothesised that the ‘magic bul-
let’ could be developed to combat malignant disease.
Patient-tailored treatment entails taking into account the
molecular makeup of an individual tumour in order to target
the cancer-driving pathways and ensure a maximal anti-
tumour response. In this regard, introduction of monoclonal
antibodies (mAbs) as therapies targeted against a specific
oncogenic molecule expressed in cancer tissue, is one of the
most significant recent advances in the treatment of leu-
kaemias and solid tumours. Case in point is Trastuzumab, a
mAb targeting the HER2 receptor, which confers significant
survival benefit to a subset of HER2 overexpressing/ampli-
fied, and particularly aggressive breast cancers.
To this day, however, treatment of oestrogen receptor
(ER)-/progesterone receptor (PR)-/HER2- negative (triple
negative) breast cancer (TNBC) represents a challenge, given
the absence of well-defined molecular targets. TNBCs are
biologically more aggressive, and chemotherapy remains the
mainstay treatment option in the neoadjuvant, adjuvant and
metastatic setting. Therefore, there is a clear unmet medical
need to better understand the molecular basis of TNBC and to
develop effective targeted treatments. Dependence of TNBC
cells on Notch activity has been recently demonstrated not
only in metastatic disease, but also in primary tumours where
Notch1 and Notch4 are overexpressed and localised in the
cytoplasm and the nucleus, indicating their activated state and
conferring worse overall survival (Reedijk et al., Can Res
2005; Speiser et al., Int J Surg Path 2011). Importantly, a
subset of these breast cancers are driven by a Notch fusion
gene, which renders the cells addicted to the Notch pathway
for survival. Notch receptors are activated by the gamma-
secretase (GS) enzyme, which is increasingly gaining recog-
nition as a relevant target in human malignancies. Gamma-
secretase is composed of Presenilin, Aph-1, Presenilin
enhancer protein (PEN-2) and Nicastrin (NCSTN). Gamma-
secretase inhibitors (GSIs) are small molecules that inhibit the
catalytic activity of Presenilin within the GS, thereby being
responsible for the unselective inhibition of the wide range of
GS substrates (Her4, CD44, E-cadherin, N-cadherin, MUC-1,
EPCAM etc.), in addition to Notch receptors. Nicastrin
(NCSTN) is the key component of GS, as it enables its com-
position, maintains enzyme stability and executes GS-sub-
strate recognition (De Strooper Cell 2005). Recently, a
gamma-secretase independent function of NCSTN has been
proposed, in the process of controlling p53-mediated cell
death via the Akt pathway. Nicastrin is also the only compo-
nent of the GS with a single-pass trans-membrane domain and
a large extracellular domain containing functional regions.
We previously validated NCSTN as a target in breast cancer
by demonstrating that it is overexpressed in breast cancer
tissue compared to normal breast, where its abundance confers
worse overall survival in the ER-negative cohort. Further-
more, we have shown that NCSTN is involved in sustaining
the invasive phenotype in TNBC, while its genetic depletion
using siRNA and shRNA is sufficient to inhibit tomour growth
in vitro and in vivo. We then introduced the concept of tar-
geting NCSTN using antagonistic antibodies [1], which has
since been followed up in mouse models of T-ALL [2]. Using
genetic immunisation, we have developed mAbs against
NCSTN extracellular domain, as a modality to block NCSTN-
driven signalling in invasive breast cancer cells. The major
findings of our study centre on the anti-tumour and anti-met-
astatic effects obtained by targeting NCSTN using our
mAbs in TNBC, in vitro and in vivo. Finally, we propose that
assessing NCSTN mRNA expression status in patient tissue,
using a novel, in situ RNA hybridization technology (RNA-
Scope), may be exploited in the clinic for tailored patient
stratification and monitoring of treatment efficacy.
Results
We raised anti-NCSTN monoclonal antibodies (mAbs) by
genetic immunisation using cDNA, encoding for the extra-
cellular domain of NCSTN (34-669 a.a.) (Supplementary
Fig. 1a). A dual discrimination approach was used to identify
only those clones that recognised endogenous NCSTN on the
surface of breast cancer cells, and inhibited their invasion
capacity. Of the 21 mAb clones screened by FACS and the
transwell invasion assay, ten clones (1E2, 1H4, 2H6, 6H5,
6H11, 9G7, 9F1, 10C5, 10C11, 10E9) recognised endogenous
NCSTN on non-permeabilized MDA-MB-231 cells and of
those seven emerged as candidates from the transwell inva-
sion assay (1H4 (44 ± 12.4 %), 2H6 (60 ± 5.6 %), 6H5
(39 ± 2.6 %), 6H11 (40 ± 6.4 %), 9G7 (42 ± 11.2 %),
10C5 (65 ± 10.2 %) and 10C11 (50 ± 10.3 %), while three
clones (1E2, 9F1 and 10E9) had no functional effect (Sup-
plementary Fig. 1b, c).
We identified mAb clone-1E2 was to serve as a ‘binding-
only control’ since it had no effect on invasion despite rec-
ognising cell surface NCSTN by FACS, while 2H6 and
10C11 were pursued as lead candidates. Their binding to
endogenous NCSTN was confirmed in other TNBC cell
lines (BT549, HCC1806) (Fig. 1a), where it was superior
compared to binding to surface NCSTN on a luminal A
breast cancer cell line (T47D). The binding of whole IgGs
was measured directly by ELISA. The antigen used was the
mammalian NCSTN ECD-Fc fusion protein (Fusion Anti-
bodies). Surface plasmon resonance was used to epitope
map the anti-NCSTN mAbs by determining which ones
compete for binding to the NCSTN antigen. An indicated
mAb was immobilized onto the surface of the BIACore chip,
which was then exposed to the flow of the human NCSTN-
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Fc protein. The sensogram registered a consequent increase
in the chip weight corresponding to the association part of
the curve. Next, a chosen Fab fragment was injected and
flown over the chip surface. We observed that 10C11 and
1E2 clones are binding overlapping epitopes, while 10C11
and 2H6 clones are directed against spatially distinct regions
on the NCSTN ECD (Fig. 1b). The mAbs displayed mod-
erate to high affinities on immobilised NCSTN ECD with Kd
values of 0.61 nM (10C11), 3.7 nM (1E2) and 21.6 nM
(2H6). Cell-based quantitative FACS on non-permeabilized
MDA-MB-231 cells established avidities of all three clones
(Table 1; Supplementary Fig. 2). As well as being physio-
logically relevant, these cellular Kd values suggested pre-
dominantly monovalent binding or other GS complex-
related steric factors involved. Since functional, purified GS
from mammalian cells contains predominantly mature,
membrane-anchored NCSTN [3], it is of importance that
2H6 and 10C11 were particularly effective in recognising
and immunoprecipitating NCSTN from the cellular mem-
brane fraction containing the active protein [4] (Fig. 1c, d).
Fig. 1 Binding properties of anti-nicastrin monoclonal antibodies in
cell-based and non-cell-based assays. a Non-permeabilized MDA-
MB-231, BT549, HCC1806 and T47D cells were incubated with the
Rat IgG2b isotype control (blue), 2H6 (green) and 10C11 (pink) at
50 lg/ml. Anti-Rat-FITC conjugate was used as a secondary
antibody. Histograms indicate a shift upon binding of the anti-
NCSTN mAbs to NCSTN on cancer cells. b BIACore binding
competition. Monoclonal antibody clone 10C11 was immobilised
directly onto a CM5 chip and the antigen, NCSTN-Fc was flowed
over at 1 mM concentration. NCSTN binding ‘start’ and ‘end’ is
marked with ‘A’ and ‘B’, respectively. After a short period to allow
for any weak dissociation, the test monoclonal antibodies (1) 10C11,
(2) 2H6, and (3) 1E2 were flowed over as Fab fragments at 1 mM
concentration. The start and ends are marked with ‘C’ and ‘D’,
respectively. Additive binding (indicating a separate, non-overlapping
epitope) is seen as a further increase in the sensogram signal, whereas
competitive binding is seen as a dissociation curve. Clone 2H6 is
shown to bind additively with clone 10C11. c, d Cell fractionation
was performed using the ProteoExtract Transmembrane Protein
Extraction Kit (Novagen). Immunoprecipitation was done with 2H6
and 10C11 mAbs, and Western blots were probed using the nicastrin
polyclonal antibody developed at Biogenes, GE against the nicastrin
extracellular domain protein. e Nicastrin deglycosylation using
EndoH and PNGase from whole cell lysates of MDA-MB-231 cells.
Upon complete NCSTN deglycosylation with PNGase, 1E2, 2H6,
10C5 and 10C11 mAbs recognise the NCSTN non-glycosylated core
protein at 80 kDa. This suggests that the mAbs bind peptide regions
on the NCSTN ECD. Cell fractionation experiment showing that the
10C11 mAb is most specific for membrane bound Nicastrin.
Immunopreciptation of NCSTN from both the cytoplasmic (cyto)
and the membrane (memb) fractions of MDA-MB-231 cells using
10C11 and 2H6 MAb confirms that these mAbs binds membrane
NCSTN. e Western blotting and glycosidase treatments of nicastrin in
cellular extracts of MDA-MB-231 cells are shown. EndoH and
PNGase treatments show the sensitivity of the various bands to
deglycosylation. Native, fully deglycosylated nicastrin migrates
at * 80 kDa, which corresponds to the predicted molecular weight
for the native protein. Treatment with PNGase produced a de-
glycosylated form of nicastrin detected by mAbs
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Fig. 2 In vitro functional effects of anti-nicastrin monoclonal
antibodies on breast cancer cells. a Treatment of triple negative
breast cancer cells with anti-NCSTN mAbs inhibits growth of acini-
like structures. MDA-MB-231, BT549, HCC1806 cells (1 9 103/
chamber) were plated in the 3D Matrigel overlay experiment. Cells
were cultured in the media containing 2 % Matrigel, supplemented
with the isotype control Rat IgG antibody and the 2H6 and 10C11
mAbs at 100 lg/ml. Treatment was added upon plating and every
48 h until Day 6. Cells were then imaged using the phase contrast
microscopy. Magnification 920 b MDA-MB-231 cells were treated
with indicated anti-NCSTN mAbs and subjected to the transwell
invasion assay for 72 h. Bars represent mean number of invaded
cells ± SEM from three separate experiments. Statistical difference
from the respective concentration of the IgG2b isotype control (2H6
50 lg/ml, p = 0.005; 2H6 200 lg/ml, p = 4.95E-05; 10C11 50 lg/ml,
p = 0.0007; 10C11 200 lg/ml, p = 0.0002). c Gelatin degradation
assay. MDA-MB-231 cells were treated with anti-NCSTN mAbs 2H6
and 10C11 at 100 lg/ml for 72 h, trypsinyzed and re-plated onto
FITC-Gelatin/Poly-Lysine coated glass slides where they were
incubated for 7 h and analysed for formation of invadopodia. Bars
represent fold change of gelatine degradation/cell in each treatment
condition ± SEM from three separate experiments. Calculations were
done based on randomly assessing degree of gelatine degradation/cell
in at least n = 100 cells per treatment condition. d MDA-MB-231
were treated with 2H6, and 10C11 mAbs at 100 lg/ml and allowed to
form cell spheroids, generated by hanging drop culture, which were
then embedded in polymerised Collagen I. Images reveal the
spheroids at Day 0 and Day 2, at which point cell penetration of
the collagen I matrix was apparent. Spheroids were fixed and stained
by actin staining with AlexaFluor488-Phalloidin, and entire spheroids
were visualised at magnification 92.5. e Anti-NCSTN mAbs inhibit
cancer cell intercalation between endothelial cells. Graphs show
percent of intercalated cancer cells at the designated time point
annotated. Cancer cells were filmed on HUVECs for 120 min. In each
experiment, C100 cells were analysed in at least three fields. Data are
expressed as mean percentage intercalated cells. Statistical difference
from the IgG2b isotype control (2H6 50 600, p = 0.0006; 2H6 1200,
p = 007; 10C11 600, p = 0.001; 10C11 1200, p = 0.01). f Cell-free
gamma secretase assay of purified gamma secretase which was pre-
incubated for 4 h with 2H6 and 10C11 mAbs prior to activity which
was assayed by detection of beta amyloid cleavage and detection of
the AICD cleavage product by Western blotting
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Since NCSTN is heavily glycosylated and dependent on this
post-translational modification for maturation and function,
we further explored the ability of our antibodies to recognise
NCSTN glycoforms by using EndoH and PNGase. EndoH
and PNGase treatment to remove the post-translationally
added glycans revealed that 2H6 and 10C11 recognised the
non-glycosylated protein at *80 kDa (Fig. 1e) [4], indi-
cating that the mAb-binding epitopes are likely to represent
peptide regions with conformation not entirely dependent on
maturation through glycosylation.
Next, we assessed therapeutic potency of anti-NCSTN
mAbs in a variety of in vitro, three-dimensional, Matrigel/
Collagen I-based assays, allowing for incorporation of the
physiologically relevant, tumour cell-extracellular matrix
interactions [5]. In such conditions, both purified 2H6 and
10C11 mAbs potently inhibited Matrigel acini formation in
a panel of TNBC cell lines (MDA-MB-231, BT549,
HCC1806) (Fig. 2a). Moreover, grape-like acini converted
to rounded structures upon mAb treatment, indicating that
the invasive capacity of the cells was being attenuated [6],
which was confirmed in a designated Boyden chamber assay
(Fig. 2b). Clone 2H6 was superior in attenuating gelatin
degradation by cellular invadopodia protrusions (Fig. 2c), as
well as the invasive capacity of MDA-MB-231 spheroids
into Collagen I (Fig. 2d), with an average increase of sphere
volume from Day 0 to Day 2 of 20.1-fold for the Control IgG
and 16.8-fold for the 2H6-treated spheres (p = 0.03). To test
whether NCSTN antibodies might affect the extravasation
step of metastasis [7], we followed the interaction of MDA-
MB-231 cells with endothelial cells by time-lapse micros-
copy [8]. Treatment of MDA-MB-231 cells with 2H6 and
10C11 did not affect the initial contact and adhesion
between cancer cells and endothelial cells: however, it
delayed the intercalation of MDA-MB-231 cells within the
endothelial monolayer after 1 and 2 h of interaction
(Fig. 2e). Moreover, only 2H6 inhibited the enzyme activity
of the purified GS by[50 % (Fig. 2f) [9].
In vivo effects of the anti-NCSTN mAbs were evaluated in
two independent xenograft models. First, in an orthotopic
model of breast cancer using luciferase labelled MDA-MB-
231 cells implanted into mammary fat pads of nude mice, 2H6
antibody inhibited tumour growth by 50 % (p = 0.007) with
concomitant Ki67 reduction, compared to the 35 % inhibition
by 10C11 and negligible effects using RO4929097 GSI
(Fig. 3a, b). Key to our premise that anti-NCSTN therapy
may be distinct from small molecule GS inhibition, mice
showed no histological evidence of Goblet cell hyperplasia in
the antibody treated arms, while these effects were detectable
in the GSI-treated animals [10] (Fig. 3c). Analysis of the
excised tumours showed that 2H6 and 10C11 inhibited Notch
activity as assessed by Notch target genes (Hes1, Hey1), as
well as key molecular regulators of cancer cell invasion and
tumour-stroma cross-talk (MMP7, MMP9, CD147 and Akt1/
2, p100 a-catalytic (110 kDa) subunit of the PI3-kinase) [11,
12] (Fig. 3d, e). Secondly, in a metastatic xenograft model
generated by tail vein inoculation of luciferase labelled
MDA-MB-231 cells [13], a greater than 70 % reduction (2H6
vs. IgG, p = 0.0006; 2H6 vs. PBS, p = 0.0027) in metastatic
growth was seen in the 2H6-treated animals (Fig. 4a–e,
Supplementary Fig. 3 a–e4). Proliferative index Ki67 was
reduced in metastatic deposits of 2H6-treated mice only
(Fig. 4f), and we noted concomitant attenuation of Notch
target genes (Hes1, Hey1, Hey2, HeyL), as well as key
mediators of metastasis, such as periostin, MMP7, MMP9
[14, 15] (Fig. 4g, h). Safety of the antibody treatment was
further confirmed by undisturbed body weight, liver and
kidney function tests (Supplementary Fig. 4). The absence of
side-effects could be readily interpreted as our mAbs recog-
nise the murine NCSTN orthologue (Supplementary Fig. 4).
Having demonstrated that anti-NCSTN mAb therapy
may be efficient in TNBC, we next attempted to identify the
optimal co-diagnostic approach, with potential clinical
translational utility. NCSTN validity as a target comes from
its overexpression in breast cancer, as well as gene ampli-
fication in a subset of breast cancers, correlating with
adverse overall survival [1] (Supplementary Fig. 5 a, b).
Analysis of the Nature TCGA cohort [16] revealed a subset
of genes (n = 21) (Supplementary Table 1, 2) co-amplified
and concomitantly mutated (n = 2) only in NCSTN-
amplified cases, proposing potential novel molecular
determinants contributing towards oncogenic signalling in
selected breast cancer cases. To complement our own
immunohistochemistry [1] and the Nature TCGA
2012/cBioPortal amplification-data, we have utilised a novel
RNA in situ hybridization platform (RNAScope; Advanced
Cell Diagnostics, Hayward, CA) [17], in a large oestrogen
receptor alpha negative (ERa-ve) cohort of breast cancer
patients (n [ 300). This allowed single-cell visualisation of
NCSTN mRNA transcript levels and establishment of a
corresponding H-score as described in the supplementary
methods. Median H-score of 120 was used as cut-off for
statistical correlations with survival and patient/tumour
characteristics. This demonstrated that high NCSTN RNA-
Scope score of C120 (0–400), strongly predicted worse
disease-free survival (p = 0.019) over a 10-year follow-up
(Supplementary Fig. 5 c, d), and represented an independent
prognostic marker in multivariate analysis with tumour
grade, stage and size (p = 0.044) (Supplementary Table 3).
Importantly, it positively correlated with NCSTN membrane
expression assessed by immunohistochemistry, high Ki67
proliferative index, pleomorphism, mitotic rate of cancer
cells, as well as aberrant cytoplasmic BRCA1 expression
(Supplementary Table 4). Given that the NCSTN RNA-
Scope was assessed in a pre-selected ERa-ve cohort, where
[95 % of tumours were of grade 3 and size above 1.5 cm,
these correlations indicate that high levels of NCSTN
Breast Cancer Res Treat (2014) 148:455–462 459
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mRNA transcript contribute to the aggressive nature of the
ERa-ve disease.
Discussion
Our current study uses cellular, pre-clinical assays to
demonstrate the importance of anti-NCSTN mAbs as
multi-faceted therapeutics for TNBC.
The only major type of breast cancer for which no specific
approved targeted therapy is available to improve patient out-
come, is the triple negative subtype (Lehmann et al., JCI 2011).
For this reason, it is essential that we identify molecules that are
driving development and progression of TNBC. Gamma-
secretase enzyme can currently be targeted by gamma-secre-
tase inhibitors (GSIs) (RO4929790, PF-03084014, MK-0752,
BMS-906024, BMS-986115), which are in multiple clinical
trials in haematological malignancies and advanced/meta-
static/refractory solid tumours (Arcaroli et al., Drugs of the
Future 2012). In breast cancer cells, single-agent GS inhibition
does not greatly affect cell proliferation in vitro and in vivo, and
metastatic models are lacking. Furthermore, rare cell lines and
patient tumours with a Notch1 fusion gene, resulting in con-
stitutively active Notch1, are most receptive to single-agent
GSI growth inhibition (1), encouraging efforts to identify
additional modalities to inhibit GS in cancer. Furthermore, true
patient stratification methods lack for gamma-secretase inhib-
itor administration, as gamma-secretase activity levels or the
expression levels of the gamma-secretase inhibitors’ target,
Presenilin, in cancer tissues, are not being evaluated. An opti-
mal target for monoclonal antibody (mAb) therapy in cancer is
a molecule expressed on the cell surface of the tumour cells,
Fig. 3 In vivo effects of anti-nicastrin monoclonal antibodies in the
orthotopic mouse model of triple-negative breast cancer. a–e In vivo
model of triple-negative breast cancer MDA-MB-231 cells. MDA-
MB-231-luc-D3H2LN cells were injected into mammary fat pads of
BalbC nude mice, and tumours were allowed to grow to 100 mm3.
Animals were randomly stratified into control and treatment (2H6,
10C11 and RO4929097) groups. Animals were treated by i.v.
injection of 2H6 and 10C11 at 50 mg/kg every 5 days (total of 5
doses), and GSI was administered by oral gavage daily at 10 mg/kg.
Tumours were measured every 4 days using callipers. Mean tumour
volumes ± S.E.M. are plotted. Statistical Analysis: The data was
statistically analysed using the Statistical Package for Social Sciences
(SPSS)/15.0. For examining the improvement in the dependent
variables on days 13–25 using two-way Repeated ANOVA was used.
f Haematoxilin Eosin and Ki67 immunohistochemistry staining of
excised and paraffin embedded. g, h RT-qPCR analyses of genes from
excised mammary fat pad tumours. Fold change of relative mRNA
levels in treated animals compared to control is represented.
Normalisation was done to GAPDH. Each coloured circle corre-
sponds to an individual animal
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whose expression and function contribute to the development
and/or progression of the disease, and the inhibition of which
selectively targets the cancer cells while inducing minimal
side-effects. We have demonstrated that Nicastrin is a candi-
date therapeutic target in invasive breast cancer, druggable
using a targeted blocking antibody.
Fig. 4 In vivo effects of anti-nicastrin monoclonal antibodies in the
metastatic mouse model of triple-negative breast cancer. a–e MDA-
MB-231-luc-D3H2LN (1 9 106) were injected into tail veins of
BalbC nude mice, and treatment was initiated 72 h post cell
inoculation. Anti-NCSTN monoclonal antibodies (2H6 and 10C11)
and control rat IgG were administered i.v. at 50 mg/kg in 5-daily
intervals, while the RO4929097 was given by oral gavage at 10 mg/
kg/day. Mice were imaged weekly from dorsal and ventral views for
5 weeks to monitor development of metastasis. Bioluminescent
imaging was performed with a highly sensitive, cooled CCD camera
mounted in a light-tight specimen box (IVISTM; Xenogen). Imaging
and quantification of signals were controlled by the acquisition and
analysis software Living Image (Xenogen). Relative Luminescent
Units were representative of tumour burden. All groups were
compared to one another for each time point by 1-Way ANOVA
(Kruskall-Wallis) and Dunn’s Multiple Comparison Test to compare
individual groups. Total luciferase flux is expressed as a log scale.
*p \ 0.05. f Haematoxilin & Eosin and Ki67 immunohistochemistry
staining of excised and paraffin embedded-lung tissues. Black dotted
lines demark metastatic tumour deposits. Ki67 staining is visualised
as nuclear. g, h RT-qPCR analyses of genes from excised lung
metastasis. Fold change of relative mRNA levels in treated animals
compared to control is represented. Normalisation was done to
GAPDH. Each coloured circle corresponds to an individual animal
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Our current study uses cellular and pre-clinical assays to
demonstrate the importance of anti-NCSTN mAbs as multi-
faceted therapeutics for TNBC. Treatment with anti-NCSTN
mAbs impinged not only on cancer cell proliferation, but also
on the multiple, crucial steps of the metastatic cascade: (i) the
invasive potential, (ii) ability of cancer cells to degrade ECM
via invadopodia extension, as well as (iii) trans-endothelial
extravasation efficiency, were all inhibited. Importantly, this
translated into attenuation of primary tumour and metastatic
growth in vivo. Previous work established that ant-NCSTN
mAbs which bind the proximal part of the ECD (41-163 a.a.)
fail to inhibit GS activity. Equally, anti-NCSTN mAb
A5226A which binds to Arg391 fails to recognise murine
orthologues, hindering in vivo toxicity assessment. Our
BIACore and functional data propose that 2H6 and 10C11,
which have differential pharmacological and functional
properties, bind distinct epitopes on NCSTN ECD. This is
currently being confirmed by peptide-based epitope map-
ping, as well as NCSTN deletion mutants (kind gift of Prof
Christian Haass, Ludwig-Maximilians-University Munich,
GE) [2, 18]. In terms of translating our results collectively
into a clinically applicable scenario, given that NCSTN is
overexpressed in a subset of breast cancers, clinical stratifi-
cation of patients eligible for NCSTN-targeted therapy could
take the form of an RNAScope test for evaluation of target
expression levels, while the 2H6 antibody can be considered
for affinity maturation and humanisation for ultimate intro-
duction into Phase I clinical trials. A companion diagnostic/
therapeutic approach like this has the potential to open up this
challenging target beyond breast cancer therapy.
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